Epigenetic modifications are a driving force in carcinogenesis. However, their role in cancer metastasis remains poorly understood. The present study investigated the role of DNA methylation in the cervical cancer metastasis. Here, we report evidence of the overexpression of DNA methyltransferases 3B (DNMT3B) in invasive cervical cancer and of the inhibition of metastasis by DNMT3B interference. Using methyl-DNA immunoprecipitation coupled with microarray analysis, we found that the protein tyrosine phosphatase receptor type R (PTPRR) was silenced through DNMT3B-mediated methylation in the cervical cancer. PTPRR inhibited p44/42 MAPK signaling, the expression of the transcription factor AP1, human papillomavirus (HPV) oncogenes E6/E7 and DNMTs. The methylation status of PTPRR increased in cervical scrapings (n ¼ 358) in accordance with disease severity, especially in invasive cancer. Methylation of the PTPRR promoter has an important role in the metastasis and may be a biomarker of invasive cervical cancer.
INTRODUCTION
Cervical cancer remains one of the leading causes of death in women worldwide. 1 The etiological role of the human papillomavirus (HPV) has led to the development of vaccines. 2 The HPV oncoproteins E6 and E7 are the major viral proteins responsible for cervical cancer initiation and progression. The p53 and retinoblastoma proteins are well-characterized targets of HPV E6 and E7. 3 From the premalignant to the malignant state, cervical lesions after HPV infection represent a spectrum of histological abnormalities, from cervical intraepithelial neoplasia 1 (CIN1), CIN2, CIN3 and carcinoma in situ (CIS) to invasive cancer. Although most women are infected with HPV at some time, most of these infections are transient and only very few progress to invasive diseases. 4 The driving force behind the stepwise progress from precancerous lesions toward invasive cervical cancer remains largely unknown. It may take several years for progression from an in situ neoplasm to invasive carcinoma. The mechanism that keeps pre-malignant cells in check and the colonial evolution that selects cells with invasive or metastatic potential also remain unidentified.
Both genetic and epigenetic modifications contribute to the molecular basis of cancer. Genomics analysis identified defined genetic signatures in metastatic cells. 5 Specific changes in gene expression in metastatic cells could result from epigenetic changes, such as DNA hypermethylation, which subsequently inactivate some metastasis suppressor genes. Increasing evidence indicates the importance of epigenetic regulation in response to environmental cues in cancer metastasis. 6 Together with genetic changes, epigenetic modifications can be a driving force in early cancer initiation, promotion and progression. 7 However, the current literature provides only limited understanding of the mechanisms underlying epigenetic alterations and their relationship with metastasis. 8 Our understanding of epigenetic modifications in cancer metastasis lags behind our knowledge regarding the genetics of this phenomenon. 8, 9 Viral infections may cause cancers and induce epigenetic changes in host cells. 10 After HPV infection, cervical epithelia must accumulate other genetic and epigenetic changes to become an invasive cancer. 11 The stepwise progression of precancerous lesions to in situ carcinomas and invasive cancers is well defined in cervical cancer and this type of cancer is an ideal model for understanding the epigenetic alterations involved in cancer invasion and metastasis. Previous studies, including our own, revealed the presence of epigenetic alterations, such as DNA methylation, in the cervical cancer. 12 --18 Using a methylomics approach, we identified a LIM-homeobox gene, LMX1A, as a metastasis suppressor that undergoes DNA-methylation-mediated silencing, subsequently allowing the in situ cancer to invade and metastasize via an incomplete epithelial --mesenchymal transition (EMT). 13 We hypothesize that de novo DNA methylation of some unknown genes may constitute an important mechanism that is responsible for the failure to keep dysplastic cells in situ. The present study investigated the role of DNA methylation in cervical cancer metastasis and discovered a tumor suppressor gene, phosphatase receptor type R (PTPRR), inhibiting MAPK signaling.
RESULTS
Dysregulation of DNA methyltransferases 3B (DNMT3B) in invasive cervical cancer The copy number and mRNA level of DNMT3B appear to increase in cervical cancer. 19 To explore the association between DNA methylation and cervical cancer invasion, the expression of DNMT genes, including DNMT1, 3A and 3B, was assessed. The mRNA transcripts of DNMT3B were significantly overexpressed in a cervical cancer cell line exhibiting a highly invasive phenotype, HeLa3rd and CaSki (Figure 1a) . The overexpression of DNMT3B was confirmed in cervical cancer tissues compared with tissue from normal cervixes (Figure 1b) .
Downregulation of DNMT3B inhibits invasion and metastasis
To validate further the role of DNMT3B in cervical cancer invasion, we knocked down DNMT3B in two cervical cancer cell lines, HeLa3rd and CaSki. Knockdown efficiency was assessed using quantitative real-time PCR (qRT --PCR) and western blot (Supplementary Figure S1 ). Knockdown had no significant effects on cell proliferation in HeLa3rd cells. Its effect in CaSki cells was significant ( Figure 1c ). Cell migration and invasion were inhibited significantly in both cell lines in vitro (Figures 1d --g ). Tumor formation was not affected in HeLa3rd cells, but was disrupted significantly in CaSki cells (Figures 2a and b) . The metastatic potential of HeLa3rd and CaSki cells was inhibited significantly in vivo (Figures 2c--h) . Downregulation of DNMT3B affected tumor growth and metastasis in cervical cancer in vivo.
DNMT3B targets the PTPRR promoter and mediates DNA methylation To identify the genes modulated by DNMT3B that are responsible for the inhibition of metastasis, we used a methylomics approach using the methyl-DNA immunoprecipitation coupled with microarray analysis technology (Figure 3a ). Differential methylation of 255 genes was identified after DNMT3B knockdown (Supplementary Table 1 ). Online gene ontology data were checked to narrow the candidate list down to genes annotated with development; this approach identified 36 genes (Supplementary Table 2 ). From some aspects, cancer is a developmental disorder. Pathways important in development are commonly dysregulated in cancers including cervical cancers. 20 --22 Our previous experiences in the discovery of genes methylated in cervical cancer also led to developmental genes. 12 --14,17,18 In addition, DNMT3B has an important role of de novo methylation in development. 23 Therefore, we focus on development-related genes in the present study. Other potential genes may be further validated in the future. The reexpression of 26 genes after DNMT3Bi was validated using qRT --PCR (Figure 3b ). Four genes were potential candidates: methylation on the expression of the PTPRR mRNA was confirmed using treatment with a demethylation agent, 5-Aza-2 0 -deoxycytidine ( Figure 3f ). To confirm that methylation of the PTPRR promoter was mediated by DNMT3B, chromatin immunoprecipitation coupled with qPCR analysis was used to test direct binding of DNMT3B to PTPRR promoter. Binding of both DNMT3B and DNMT1 decreased after DNMT3B knockdown (Figure 3g ). Taken together, these data suggest that methylation of the PTPRR promoter is mediated by DNMT3B in cooperation with DNMT1 in cervical cancer.
PTPRR expression phenocopies DNMT3B downregulation and inhibits MAPK signaling in cervical cancer PTPRR removes a phosphate group from MAPK and affects neuron growth in the mouse, 24, 25 but its function in cancer is unknown. To binding of AP-1 to the long control region of HPV increases the expression of the E6 and E7 oncoproteins, which are an important driving force in the development of cervical cancer and maintenance of malignant phenotypes, we propose that PTPRR limits the expression of HPV oncogenes by inhibiting AP-1. The expression of E6 and E7 was suppressed in cell lines reexpressing PTPRR (Figure 5c ). EMT is an important phenomenon in cancer invasion and is related to MAPK pathway. 26, 27 Our results showed that PTPRR downregulated EMT markers ZEB1, SIP1 and fibronectin, upregulated an epithelial marker, CDH1, in cervical cancer cell lines (Figure 5d and Supplementary Figure S5) . These results suggest that PTPRR affects the malignant phenotypes of cervical cancer by inhibiting the phosphorylation of p44/42 MAPK, which subsequently maintains the cell adhesion molecule, CDH1, and inhibits the expression of HPV oncogenes. DNMT3B was reported recently as a downstream target of MAPK signaling. 28 To test the potential reciprocal regulation of DNMT and PTPRR via MAPK signaling, we assessed the inhibition of the expression of DNMTs (Figure 5e ) and demethylation of the PTPRR promoter (Figure 5f ) after reexpression of PTPRR; our results confirmed our hypothesis. Although PTPRR expression phenocopies DNMT3B downregulation, the molecular changes, such as EMT patterns, were not identical (Supplementary Figure S5 and S6), indicating that PTPRR is not the only gene mediated by DNMT3B in cervical cancer metastasis.
An inhibitor of the MAPK pathway, U0126, was used to verify the suppressive effect of PTPRR on the MAPK pathway. Treatment with U0126 caused dephosphorylation of p44/42 MAPK, suppression of AP-1, expression of HPV oncogenes and activation of CDH1, although there were some exceptions (Supplementary Figure S7) .
PTPRR inhibits tumor formation and metastasis in vivo
Xenograft transplantation was used to analyze the effects of PTPRR on tumor formation in vivo. PTPRR significantly inhibited tumor formation induced by CaSki cells, but not by HeLa3rd cells (Figures 6a and b) . PTPRR inhibited lung metastasis associated with both cell lines in mice (Figures 6c-f) . Two mice injected with the HeLa3rd vector control had brain metastasis and were euthanized 2 months after implantation, together with two experimental mice (Figure 6ci ). The other animals were euthanized 3 months after implantation (Figure 6cii ). Pathological examination confirmed the inhibitory effect of PTPRR on metastasis (Figures 6g and h ).
Clinical relevance of PTPRR in cervical cancer
To investigate the clinical relevance of PTPRR, its protein expression levels and DNA methylation status were assessed in human tissues. Immunohistochemical examination of samples with cervical neoplasia showed that the expression of PTPRR was minimal in normal squamous epithelium and was increased in CIN. Expression was greatest in samples with in situ carcinoma, whereas it was absent in cells that had become invasive and metastatic (Figure 7a ). qMS --PCR analysis detected methylation of the PTPRR promoter in most invasive cancer tissues. Cervical scrapings are better suited to test potential clinical applications, compared with tissue samples. We analyzed cervical scrapings from patients exhibiting the full spectrum of cervical lesions. The methylation ratio of the PTPRR promoter increased with disease severity, especially at the transition from in situ to invasive carcinoma (Figure 7b ). Bisulfite sequencing confirmed the hypermethylation patterns in samples with invasive cancer, but not in samples of normal cervix (Figure 7c ). Taken together, these clinical results support our proposal that PTPRR is a tumor suppressor involved in cancer invasion and metastasis and suggest that PTPRR DNA methylation is a potential biomarker for cervical cancer screening.
DISCUSSION
To date, the role of epigenetic modifications in cancer invasion and metastasis, which are the major characteristics of cancer, has not been studied extensively. The expression of DNMTs has been reported in cancers; 29 for example, DNMT3B is overexpressed in ovarian, breast, lymphoma, kidney, bladder and colon cancers. 29 --33 Genetically, a gain of DNMT3B copy number has been reported in HPV-immortalized keratinocytes and in cervical cancer tissues. 19 The functional relevance of DNMT3B expression in cancer phenotypes is unknown, even though one report showed that interference of DNMT3B inhibits cell migration (but not invasion) in vitro in a prostate cancer cell line. 34 Our study presented data that show the unique role of DNMT3B in tumor growth and metastasis in a cervical cancer model. We also found that a previously unidentified gene, PTPRR, is silenced by DNMT3B, which leads to the activation of MAPK signaling and EMT.
As DNMT3B is thought to have a role in de novo methylation, the knockdown of DNMT3B in cancer may not affect the methylation patterns already established. However, it is doubtful that DNMT1 can maintain the methylated genome by itself, 35 especially at high-density CpG sites or repeated sequences. A supportive role for DNMT3 in the maintenance of methylation has been suggested (see review by Jones and Liang 36 ). An updated model of DNA methylation maintenance proposed that DNMT3A/ 3B interacts with nucleosomes bearing specific modifications, and then cooperates with DNMT1 and other enzymes at the replication fork to maintain methylation patterns, especially at repeats and imprinted genes. A later report suggested that the role of DNMT3B in the maintenance of DNA methylation is associated with H2AK119 monoubiquitination. 37 Three repeated sequences are close to the PTPRR promoter, at positions À32 to À72 (simple repeat), À847 to À1027 (LINE) and À1544 to À1800 (LINE), and may explain why PTPRR reexpresses after DNMT3B knockdown.
The expression of PTPRR in precancerous lesions in accordance with disease severity in tissue sections may fail to support the role of PTPRR as a tumor suppressor gene. However, its silencing in invasive cancer lesions and our in vitro and in vivo studies suggest that PTPRR is a bona fide tumor suppressor, the expression of which increases in response to oncogenic stress in precancer stages. We propose a model to explain this regulatory loop between the DNMT epigenetic machinery and MAPK oncogenic signaling. We speculate that, in oncogenic-responsive stresses, the activation of PTPRR inhibits the phosphorylation of p44/42 MAPK, which inhibits AP-1 and the subsequent expression of E6 and E7, and keeps dysplastic cells in situ. However, when oncogenic stresses overrule this checkpoint, DNMT3B expression may cooperate with DNMT1 to promote de novo methylation of some metastasis-suppressor genes. A recent report showing K-Rasinduced DNMT3B binding to the CDH1 promoter, which resulted in increased methylation and invasive migration, supports our speculation. 28 De novo methylation of PTPRR may gradually inhibit its expression, which results in the activation of MAPK signaling and its downstream effectors. In return, the activated MAPK signaling upregulates DNMTs, which then help to consolidate the methylation silencing of PTPRR (Supplementary Figure S8) . Understanding what and how the stresses overrule the guardian function of PTPRR may lead to new approaches to prevent and treat cancer. Protein phosphorylation is important in cell signaling and in the regulation of cellular functions. The balance of protein tyrosine phosphorylation is a dynamic process that is controlled by tyrosine kinases and protein tyrosine phosphatases (PTPs). PTPs are classified by domain and fall into two subgroups: the receptor type (those with transmembrane domains and receptor-like extracellular domains) and the nonreceptor type (those without transmembrane domains). In cancer development, the tumorsuppressive or oncogenic role of PTPs may depend on the substrates. The expression of receptor-type PTPs, such as PTPRA, PTPRE, PTPRF and PTPRH, is increased in tumors, but the effects of this increase in cancers are not clear. 38 The receptor-type PTPs, such as PTPRD and PTPRO, are tumor suppressors; PTPRD inhibits tumor growth in glioblastoma 39 and PTPRO reduces proliferation and anchorage-independent growth in lung cancer. 40 The PTPRR knockout mouse has defects in motor coordination and balance. 41 The roles of PTPRR in development and cancer are not clear. The association between PTPRR and cancer was reported only recently for colon cancer. 42 The methylation of PTPRR can be detected in precancerous colorectal lesions, suggesting a role for this protein early in colon cancer development. However, the mechanistic relevance of PTPRR in cancer biology has not been reported. PTPRR dephosphorylates p44/42 MAPK in response to some growth factors in cell lines. 24, 43, 44 Molecules that inhibit the MAPK signaling, such as nonmetastatic 23, Raf kinase inhibitor protein, mitogen-activated protein kinase kinase 4 and mitogen-activated protein kinase kinase 6, inhibit metastasis. 45, 46 We characterized the tumor-suppressor function of PTPRR, especially its role in metastasis via the MAPK pathway, in a cervical cancer model. The effects of PTPRR reexpression and the specific p44/42 MAPK pathway inhibitor, U0126, were not the same, suggesting that PTPRR affects malignant phenotypes by dephosphorylating other substrates, such as ERK5 and p38 MPAK, as shown in other species. 43, 47 The extent of kinases targeted by PTPRR in cancer remains to be investigated.
HPV is necessary for the development of cervical cancer, with the expression of the viral oncoproteins E6 and E7 being the driving force. 2, 48 The long control region of HPV is regulated by many transcription factors, including AP-1.
49,50 AP-1 transcription factors, such as Fra-1, c-Fos and c-Jun, are the downstream targets of the MAPK pathway and affect cancer cell growth and metastasis. 51 --54 In cervical cancer, both the AP-1 and MAPK pathways are activated, although the mechanism of MAPK pathway activation is not clear. 55 --57 Our study demonstrated that the DNA-methylation-mediated silencing of PTPRR contributed to the activation of MAPK pathways in cervical cancer. The binding of AP-1 to the long control region increases promoter activity, and the expression of E6/E7 correlates with cervical cancer progression. 49 --50,57 Although the modulation of E6/E7 expression by AP-1 was known to affect cell growth rather than metastasis in cervical cancer, the ability of AP-1 in promoting metastasis through EMT in many cancers were reported. 52, 58, 59 In addition, repression of E7 was reported to restore CDH1 expression in cervical cancer. 60 The different effects of DNMT3B interference on phenotypes of HeLa3rd and CaSki are interesting. These differences may be HPV genotype or cell type dependent. The HPV E7 oncoprotein was recently reported to bind to, and to augment, DNMT1 enzyme activity, which causes the epigenetic suppression of CDH1. 61, 62 However, the differential interactions between E7 from different HPV genotypes and DNMT1 remain unknown. We speculate that the expression of PTPRR may suppress E7 expression, inhibit the E7-DNMTs-mediated epigenetic effects and inhibit cancer progression. However, the interaction between E6 or E7 and DNMT3B has not been reported. The interactions between HPV oncoproteins and DNMT3A/B also warrant further investigations. The extent to which our proposed model is amplified in relation to HPV oncogenes and HPV-related tumors, such as head and neck cancer, remains to be determined. 63 EMT has been studied extensively as a mechanism of cancer invasion. 64, 65 In the present study, PTPRR affected the invasion and metastasis phenotypes of cervical cancers without changing the complete set of EMT markers. Accumulating evidence, including our previous study, supports the role had by incomplete EMT in cervical cancer progression. 13, 64 Changes in EMT markers could begin as early as the immortalization of cells after HPV infection. 66, 67 An incomplete EMT is sufficient to induce metastasis. 68 From the clinical point of view, DNA methylation has been proposed as a potential biomarker for cervical cancer detection. 16 The feasibility of using methylation markers for cervical malignancy screening has been appraised critically. 16, 69, 70 Various genome-wide strategies have been used to discover genes undergoing methylation silencing in cervical cancers and suggest the potential for some newly discovered genes. 17, 71, 72 Our present study found that PTPRR is highly methylated in invasive cancer tissues. Although protein expression in CIS is high, we detected the DNA methylation of PTPRR, indicating the molecular propensity of some in situ cells toward cancer invasion. This methylation was detected in cervical scrapings and may provide a specific biomarker for cervical cancer screening. The discrepancy between PTPRR protein expression and DNA methylation may attribute to the difference of methodology. Protein expression revealed by Immunohistochemistry may not identify cells with DNA methylation, which can be detected by MS --qPCR. Therefore, both PTPRR protein expression and methylation can be detected in CIS lesions. Although the detection of PTPRR methylation in CIN lesions is not satisfactory, the specificity for high-grade lesions is very high, which may contribute to the potential gene panel for cancer detection. Further standardization of the methylation assay and use of validation tests in women with different geographic and ethnic backgrounds may help validate these results and translate this bench discovery to a better cervical cancer screening in the future.
MATERIALS AND METHODS
Please refer to the supporting information online for a detailed description of the experimental procedures.
Patients
Cervical scrapings and tissues were from a hospital-based, retrospective, case-control study at the National Defense Medical Center, Taipei, Taiwan as described previously. 15 Informed consent was obtained for all patients involved in this study and this study was approved by the Institutional Review Board of the Tri-Service General Hospital, Taipei, Taiwan. Cervical scraping DNA were collected on 338 patients, including women who had a normal uterine cervix (n ¼ 161), CIN1 (n ¼ 38), CIN2 (n ¼ 39), CIN3/CIS (n ¼ 60), squamous cell carcinoma (SCC) or adenocarcinoma (n ¼ 60). Cervical cancer tissue DNA were collected on 53 patients including women who had SCC (n ¼ 34) and adenocarcinoma (n ¼ 19). Cervical tissue RNA were collected on 23 patients including women who had normal uterine cervix (n ¼ 7) and SCC (n ¼ 16). Cytological, histological and clinical data for all patients were reviewed by a panel of colposcopists, cytologists and pathologists. The uterine cervix diagnoses were according to histological reports except normal uterine cervix, which were according to cytological reports. Normal cervixes in the tissue array and for RNA extraction were obtained from patients with benign gynecological diseases. The diagnoses were made by histopathology.
Cell lines, culture conditions and constructs
The human cervical cancer cell lines HeLa3rd and CaSki were used in this study. The process of selecting subline (HeLa3rd) is described in Supplementary Information. 18 Briefly, HeLa cells were seeded into the transwell inserts (BD Bioscience, San Jose, CA, USA) that coated with Matrigel (BD Biosciences) and incubated for 72 h at 37 1C. The cells that migrated through the membrane and attached to the lower chamber were harvested and expanded for the second round of selection. The subline of the third-round selection was designated as HeLa3rd. DNMT3B RNAi (5 0 -GATCCCCAGATGACGGATGCCTAGAGTTCAAGAGACTCTAGGCATCCGTCA TCTTTTTTGGAAA-3 0 . Sequences in underlined are RNAi sequence) 73 was cloned into pSuper vector (OligoEngine, Seattle, WA, USA). PTPRR (NM_130846) was constructed by inserting a full-length cDNA product into a pT-REx-DEST31 Gateway Vector (Invitrogen, Carlsbad, CA, USA).
RNA extraction, cDNA synthesis and qRT --PCR Total RNA was isolated from each sample using a Qiagen RNeasy kit (Qiagen, Hilden, Germany). RNA was reverse transcribed to cDNA using the SuperScript III first-strand synthesis system for RT --PCR (Invitrogen). qRT --PCR was performed using RT 2 SYBR Green qPCR Master Mixes (SABiosciences, Frederick, MD, USA) in an ABI 7500 Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA). The primers used in this study are shown in Supplementary Table S3. Demethylation treatment, bisulfite modification, qMS --PCR and bisulfite sequencing Cells were treated with DMSO or 5-Aza-2 0 -deoxycytidine (Sigma, St Louis, MO, USA) for the demethylation and gene reexpression analysis. DNA and RNA were extracted for further analysis after treatment. Bisulfite modification was performed using a CpGenome Fast DNA Modification Kit (Millipore, Bedford, MA, USA). qMS --PCR was performed in a TaqMan probe system using the LightCycler 480 Real-Time PCR System (Roche, Indianapolis, IN, USA). PCR products for bisulfite sequencing were cloned into yT&A vector (Yeastern Biotech, Taipei, Taiwan) and then sequenced.
Methyl-DNA immunoprecipitation coupled with microarray analysis
Methyl-DNA immunoprecipitation was performed as described previously in the literature 74 with anti-5-methyl cytosine antibody (ab1884; Abcam, Cambridge, UK). The immunoprecipitated DNA was amplified using a whole-genome amplification kit (WGA2, Sigma). Amplified DNA was hybridized to HG18_promoter 2 array (Roche NimbleGen, Madison, WI, USA).
Chromatin immunoprecipitation coupled with qPCR
Chromatin immunoprecipitation assays were performed according to the protocol from Millipore (EZ --Magna ChIP G Chromatin Immunoprecipitation Kit, Millipore). The antibodies used in the chromatin immunoprecipitation coupled with qPCR analysis were anti-DNMT3b (ab13604, Abcam), anti-DNMT1 (ab16632, Abcam) and anti-mouse IgG (ab37355, Abcam).
Cell proliferation, migration and invasion assays Cells were seeded in 96-well plates at a density of 2000 cells per well. On days 0, 1, 2, 3 and 4, cell viability was measured using an MTS assay (C CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay, Promega, Madison, WI, USA). Cell migration assays were performed by using an Oris Universal Cell Migration Assembly kit, as instructed by the manufacturer (Platypus Technologies, Madison, WI, USA). Cell invasion was measured in the Transwell system (BD Bioscience). The chamber membrane was coated with Matrigel (BD Bioscience).
Immunoblot analysis
The antibodies used in the immunoblot analysis were anti-DNMT3B In vivo tumorigenicity and metastasis models Six-week-old CB-17 SCID mice were used in the tumorigenicity and metastasis analysis. All animal studies were approved by the Institutional Animal Care and Use Committee of the National Defence Medical Centre, Taipei, Taiwan. In the tumorigenicity analysis, 10 6 cells from each stable line were injected subcutaneously into both flanks of each mouse. The mice were killed at day 30. To investigate the metastatic properties, 10 6 cells were injected through the tail vein. Animals were killed at 12 weeks and examined for the presence of metastases. The brain and lung were then excised, stained with Bouin's fixative and prepared for histopathological analysis. 53 Tissue microarray and immunohistochemistry Paraffin-embedded cervical tissues of Chinese patients were retrieved from the Department of Pathology, National Defense Medical Center, Taiwan. The tissue microarrays comprized histologically normal squamous epithelial samples (n ¼ 33), CIN1 (n ¼ 15), CIN2 (n ¼ 7), CIN3/CIS (n ¼ 18), SCC (n ¼ 53) and metastatic SCC (n ¼ 10). A standard protocol for immunohistochemistry was used with rabbit polyclonal anti-human PTPRR antibody (ab12153, Abcam).
Statistical analysis SPSS (version 15) for Windows (IBM, Armonk, NY, USA) was used to analyze the data. The Mann --Whitney U test was used to compare cell proliferation, migration, invasion and relative RNA expression and promoter methylation in the different stable transfectants or tissues. The significance of observed trends in methylation data of clinical swabs was determined by linear regression modeling by coding the diagnosis as an ordinal independent variable.
